rasagiline (Azilect)

TVP-1022 is the (S)-isomer and a cardioprotective agent; monoamine oxidase type-B inhibitor that is not metabolized to amphetamine derivatives; can lead to fatal hypertensive crisis in patients who consume tyramine-rich foods

Also Known As:

Networked: 243 relevant articles (41 outcomes, 79 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Youdim, Moussa B H: 40 articles (09/2015 - 04/2002)
2.	Amit, Tamar: 31 articles (09/2015 - 10/2002)
3.	Bar-Am, Orit: 22 articles (09/2015 - 10/2002)
4.	Weinreb, Orly: 16 articles (09/2015 - 09/2004)
5.	Maruyama, Wakako: 10 articles (01/2013 - 06/2002)
6.	Poewe, Werner: 9 articles (04/2015 - 05/2005)
7.	Rascol, Olivier: 9 articles (02/2015 - 05/2005)
8.	Naoi, Makoto: 8 articles (01/2013 - 06/2002)
9.	Hauser, Robert A: 7 articles (04/2015 - 08/2004)
10.	Yogev-Falach, Merav: 7 articles (01/2009 - 10/2002)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/2013 - "Rapid onset of efficacy of rasagiline in early Parkinson's disease." 08/01/2009 - "It has demonstrated efficacy in monotherapy for early Parkinson's disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients), and has shown ability to reduce off time in more advanced PD patients with motor fluctuations in two large placebo-controlled trials (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off", and Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily). " 01/01/2008 - "Rasagiline improved HR-QOL as monotherapy in early Parkinson's disease (one study), but not clearly in more advanced disease (one study). " 09/01/2012 - "In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. " 06/01/2014 - "Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial."
2.	Fatigue 01/01/2015 - "Rasagiline may be effective in reducing levels of physical fatigue in PD. " 01/01/2015 - "We found high quality evidence that rasagiline reduced or slowed down the progression of physical aspects of fatigue (one study, N = 1176, SMD = -0.27, 95% CI -0.39 to -0.16, I(2) = 0%). " 01/01/2015 - "Parkinson Fatigue Scale (mean [SE] difference, -0.42 [0.09], P < .001) and daytime sleepiness (mean [SE] difference, -0.24 [0.09], P = .006) scores also revealed significantly less worsening in the rasagiline group compared with placebo. " 02/01/2014 - "Rasagiline was associated with significantly less progression of fatigue compared with placebo over a 9-month period." 02/01/2014 - "Our aim was to assess the benefits of rasagiline treatment on fatigue in early PD patients. "
3.	Hypokinesia (Bradykinesia) 09/01/2011 - "As a monotherapy or an adjunctive therapy, rasagiline is an effective drug for reducing the severity of bradykinesia in PD patients." 09/01/2011 - "To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity. " 09/01/2011 - "In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients. " 09/01/2011 - "Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review." 09/01/2011 - "Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. "
4.	Starvation 09/01/2008 - "We specifically investigated the protective efficacy of TVP1022 and propargylamine in neonatal rat ventricular myocytes (NRVM) against apoptosis induced by the anthracycline chemotherapeutic agent doxorubicin and by serum starvation. " 02/01/2010 - "Based on the established cytoprotective and neuroprotective efficacies of propargylamine derivatives, as well as on our recent study showing that TVP1022 attenuates serum starvation-induced and doxorubicin-induced apoptosis in neonatal rat ventricular myocytes (NRVMs), we tested the hypothesis that TVP1022 will also provide protection against doxorubicin-induced NRVM functional derangements. " 09/01/2008 - "TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity." 09/01/2008 - "We demonstrated that pretreatment of NRVM cultures with TVP1022 or propargylamine attenuated doxorubicin-induced and serum starvation-induced apoptosis, inhibited the increase in cleaved caspase 3 levels, and reversed the decline in Bcl-2/Bax ratio. "
5.	Dyskinesias (Dyskinesia) 02/01/2012 - "Changes in UPDRS-ADL OFF score and total daily ON time without dyskinesia also favoured rasagiline but were not significant. " 01/01/2009 - "Compared with pramipexole, use of the rasagiline strategy was estimated to reduce costs by 18% per patient over 5 years and was associated with an additional 10% delay in dyskinesia onset (0.41 years; 95% CI 0.27, 0.55). " 01/01/2008 - "In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. " 01/01/2007 - "In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. " 03/12/2005 - "Both rasagiline and entacapone reduced mean daily off-time (-1.18 h rasagiline and -1.2 h entacapone vs placebo -0.4 h; p=0.0001, p<0.0001, respectively) and increased daily on-time without troublesome dyskinesia (0.85 h vs placebo 0.03 h; p=0.0005 for both). "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Monoamine Oxidase (MAO)
3.	Selegiline (E250)
4.	propargylamine
5.	Doxorubicin (Adriamycin)
6.	Mesylates (Mesylate)
7.	pramipexol (pramipexole)
8.	entacapone (Comtan)
9.	Rotenone
10.	Methylphenidate (Ritalin)

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Drug Therapy (Chemotherapy)
3.	Transdermal Patch
4.	Deep Brain Stimulation
5.	Polypharmacy